US3755581036
US3755581036
Gilead Sciences, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 187.44B EUR | 156.79B EUR | 173.1B EUR | 152.28B EUR |
Enterprise Value | 203.68B EUR | 179.85B EUR | 187.64B EUR | 169.65B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | 18.78x | 21.16x |
Forward P/E | 15.24x | -- | -- | -- |
Price to Sales | 6.15x | 5.15x | 5.82x | 6.69x |
Price to Book | 15.86x | 13.26x | 7.36x | 6.71x |
EV/Revenue | 6.69x | 5.91x | 6.31x | 7.45x |
EV/EBITDA | 13.95x | 12.15x | 12.51x | 14.72x |
Price to FCF (P/FCF) | 19.19x | 12.11x | 16.92x | 19.52x |
EV/FCF | 20.85x | 13.9x | 18.34x | 21.74x |
FCF Yield | 5.21% | 8.26% | 5.91% | 5.12% |